Blog

  • Barclays Favors Safestore as Big Yellow and Shurgard Face Growth Risks

    Barclays Favors Safestore as Big Yellow and Shurgard Face Growth Risks

    Barclays upgraded Safestore (LSE:SAFE) to “overweight” from “equal weight” on Monday while downgrading Big Yellow (LSE:BYG), Shurgard (EU:SHUR) and Unite (LSE:UTG) to “underweight” as the bank reassessed its European real estate coverage using a greater emphasis on free cash flow.

    The brokerage cited a combination of softer growth expectations, operational challenges and macroeconomic risks behind the rating changes.

    Barclays also lowered Merlin Properties (EU:MRL) to “equal weight” from “overweight” and Swiss Prime Site (USOTC:SWPRF) to “equal weight” from “overweight.” SEGRO (LSE:SGRO), meanwhile, was upgraded to “equal weight” from “underweight” following the board-approved takeover offer from Prologis.

    Barclays Shifts Valuation Focus to Free Cash Flow

    As part of the review, Barclays said it was replacing its previous total accounting return methodology with a framework based predominantly on free cash flow, supplemented by dividend discount models where appropriate.

    The change reflects the bank’s view that listed property companies should increasingly be valued as operating businesses capable of generating contractually supported income and expanding cash flow, rather than being assessed mainly through periodic changes in the value of their property portfolios.

    Under the revised methodology, Barclays forecasts five years of free cash flow per share. Capitalised interest, maintenance spending and other sustaining capital expenditure are deducted from recurring earnings when calculating these forecasts.

    Free cash flow typically carries an 80% weighting in the brokerage’s valuation, with dividend discount models accounting for the remaining 20%. A larger weighting may be assigned to the dividend model where cash-flow forecasts are considered less dependable.

    European Real Estate Viewed as “defensive growth”

    Barclays said European listed property should increasingly be regarded as “defensive growth”, supported by predictable contractual income and limited new supply.

    Other characteristics supporting this assessment include embedded rental reversion or indexation, manageable recurring capital expenditure, disciplined development activity and opportunities to increase cash flow through acquisitions.

    However, the outlook differs substantially between individual property segments and companies, prompting Barclays to make several significant changes to its ratings and earnings forecasts.

    Safestore Remains Preferred Self-Storage Stock

    Within self-storage, Barclays highlighted a less favourable operating backdrop than during the pandemic. Industry capacity has expanded by approximately 30% since COVID-19, while customer demand has moved away from the elevated levels recorded during that period.

    The brokerage reduced its adjusted EPRA EPS forecasts for Safestore by 3% for fiscal 2026 and by 11% for fiscal 2030. Despite these reductions, Safestore remains Barclays’ preferred exposure to the self-storage sector.

    The bank retained a 670 pence price target for Safestore, while acknowledging challenges including weaker occupancy, affordability pressures and rising customer-acquisition costs.

    Big Yellow and Shurgard Downgraded

    Barclays made larger reductions to its forecasts for Big Yellow, cutting adjusted EPRA EPS estimates by 7% for fiscal 2027 and 25% for fiscal 2030.

    The stock was downgraded to “underweight” with an 820 pence price target, with Barclays pointing to a weaker medium-term free cash flow outlook compared with Safestore.

    Shurgard was also moved to “underweight”, accompanied by a €22 price target. Barclays lowered its earnings estimates by 9% for fiscal 2026, with the reductions increasing to approximately 21%-22% for fiscal 2028 through 2030.

    The brokerage cited continuing lease-up risks and weakness across Shurgard’s existing portfolio as factors behind the more cautious stance.

    Unite, Merlin and Swiss Prime Site Ratings Lowered

    Unite was downgraded to “underweight” with a 460 pence price target. Barclays identified competitive pricing, occupancy levels and rental growth as important risks facing the student accommodation group.

    Merlin Properties was cut to “equal weight” with a €14.70 target. The bank expects higher operating costs within the company’s data-centre business, together with a partner promotion, to restrict near-term earnings growth.

    Swiss Prime Site was also downgraded to “equal weight”, with Barclays setting a 125 Swiss franc target. The brokerage said the company’s defensive qualities were becoming increasingly reflected in its current share price.

    SEGRO Upgraded Following Prologis Offer

    Barclays raised SEGRO to “equal weight” from “underweight” and set a 970 pence price target following the agreed takeover proposal from Prologis.

    The valuation is closely linked to the agreed offer of 978 pence per SEGRO share together with a 22.54 pence final dividend.

    Barclays nevertheless highlighted the potential downside should the transaction fail to complete, setting out a downside scenario of 740 pence per share in that event.

  • Tracsis Meets FY26 Expectations and Completes £48 Million Mistral Data Acquisition

    Tracsis Meets FY26 Expectations and Completes £48 Million Mistral Data Acquisition

    Tracsis (LSE:TRCS) delivered full-year trading in line with market expectations for the year ended 31 July 2026, while completing the £48 million acquisition of rail software specialist Mistral Data. Revenue increased to approximately £85.5 million and adjusted EBITDA reached around £13.5 million, with the performance benefiting from the Events division that has since been sold.

    Year-End Cash Reaches £19.4 Million

    Tracsis ended the financial year with cash of £19.4 million before taking account of proceeds from the disposal of its Events business.

    Following the sale, the group is increasingly concentrating on higher-margin software and data technology operations, with an emphasis on generating a greater proportion of recurring revenue. Management is also pursuing a more streamlined structure following the Events disposal and a series of acquisitions.

    The completion of the “One Tracsis” operating model represents another element of this strategy, bringing the group’s activities under a more integrated organisational framework.

    £48 Million Mistral Data Deal Expands Rail Software Portfolio

    Tracsis has now completed its £48 million acquisition of Mistral Data, a UK specialist in rail software. The transaction was financed through a combination of existing cash and a significant drawdown from the group’s £40 million revolving credit facility.

    Following the acquisition, pro forma net debt stands at approximately 1.5 times EBITDA.

    Mistral’s cloud-native products complement Tracsis’s existing technology portfolio and are expected to strengthen the group’s position within the UK rail software market. The enlarged business will target continued demand for digital technology designed to improve operational efficiency, safety and passenger experience across the rail industry.

    Tracsis is now focused on integrating Mistral and identifying opportunities to generate additional growth from the combined product offering.

    Acquisitions Support Software-Focused Transformation

    The Mistral transaction follows Tracsis’s recent acquisition of Vesputi and forms part of the group’s wider transformation into a more focused software and data technology business.

    Alongside portfolio changes and the implementation of the One Tracsis structure, these acquisitions are intended to increase exposure to recurring software revenues and position the company to benefit from long-term investment in transport technology and infrastructure.

    Tracsis is scheduled to publish its full FY26 results on 19 November 2026, when investors will receive further detail on the impact of the portfolio restructuring, recent acquisitions and prospects for the enlarged group.

    Financial Stability Offset by Valuation Concerns

    Tracsis’s outlook benefits from underlying financial stability, improving cash generation and positive longer-term share price momentum.

    However, profitability indicators remain mixed, while valuation represents a more significant constraint. The shares trade on a particularly elevated price-to-earnings multiple and offer a relatively low dividend yield, limiting valuation support despite the group’s improving strategic position.

    More About Tracsis

    Tracsis plc is a UK transport technology company providing software, hardware, data capture, analytics and GIS services across the rail and wider transport markets.

    Its rail technology operations cover areas including resource and asset optimisation, smart ticketing, customer-facing retail platforms and safety systems. The group’s data, analytics and consultancy activities support intelligent transport networks, smart city planning and environmental decision-making.

    Tracsis serves customers including Network Rail, UK train operating companies, the Department for Transport, Transport for London, local authorities and major engineering businesses, as well as freight and transit operators in North America.

    The group has combined organic growth with an active acquisition strategy, completing nineteen transactions since 2008 as it increasingly focuses its portfolio on software and data technologies aligned with long-term transport infrastructure investment.

  • Georgina Energy Raises £1.25 Million to Advance Hussar Drilling Programme

    Georgina Energy Raises £1.25 Million to Advance Hussar Drilling Programme

    Georgina Energy plc (LSE:GEX) has raised £1.25 million through an equity placing to support its Hussar drilling programme and provide additional working capital. The company issued 10,000,000 new ordinary shares at a price of 12.5 pence each, alongside warrants allowing participating investors to acquire further shares at 14 pence over a five-year period.

    Funding Primarily Targeted at Hussar Programme

    The majority of the proceeds will be directed towards advancing drilling activities at Hussar, with the remainder available for general working capital purposes.

    The fundraising provides Georgina Energy with additional capital as it progresses its exploration plans, although the issue of new shares will result in dilution for existing shareholders.

    Investors participating in the placing have also received warrants with an exercise price of 14 pence per share. These warrants will remain exercisable for five years and could provide the company with further funding if exercised.

    Issued Share Capital to Rise to 270.9 Million Shares

    Admission of the 10,000,000 new shares to the London Stock Exchange’s main market is expected on 27 August 2026.

    Following admission, Georgina Energy will have 270,861,707 ordinary shares in issue. The updated figure also represents the company’s total voting rights, providing shareholders with the revised denominator for determining whether they are required to disclose changes in their holdings under applicable UK regulations.

    Financial Position Remains a Key Risk

    Georgina Energy’s outlook continues to be constrained by its financial position. The company currently generates no revenue and remains loss-making, with negative cash flow and negative equity alongside increasing debt levels.

    Technical momentum provides some support, with recent indicators presenting a comparatively more positive picture. However, valuation remains difficult to assess while the company continues to report negative earnings and does not offer an indicated dividend yield.

    More About Georgina Energy plc

    Georgina Energy plc is a London-listed energy company focused on developing exploration opportunities, including its Hussar project.

    The company’s ordinary shares trade under the ticker GEX on the London Stock Exchange’s main market. Its current strategy centres on progressing its exploration and drilling programmes while using access to the UK capital markets to support project development.

  • MS International Secures €19.4 Million NATO Naval Gun Systems Contract

    MS International Secures €19.4 Million NATO Naval Gun Systems Contract

    MS International (LSE:MSI), through its defence subsidiary MSI Defence Systems, has secured a €19.4 million contract from a NATO member country for the supply of three advanced MSI-DS 30mm naval gun systems. The systems will incorporate counter-uncrewed aerial system capabilities, strengthening the company’s exposure to growing demand for multi-threat naval defence technology.

    Systems to Combine Radar, Optical Detection and Fire Control

    The three naval gun systems will incorporate radar and optical detection technologies alongside the proprietary MSI-DS Fire Control System. The integrated configuration is designed to provide protection against a range of threats, including surface vessels, semi-submersible targets and uncrewed aerial systems.

    Deliveries under the contract are expected to begin towards the end of 2027, in accordance with the customer’s wider programme schedule.

    The order adds to MS International’s defence backlog and reinforces the company’s position as a supplier of integrated naval weapon systems to NATO customers. The delivery timetable also provides additional medium-term revenue and operational visibility for the group’s defence activities.

    Strong Balance Sheet Supports Outlook

    MS International’s broader outlook is supported by solid financial fundamentals, including a conservatively financed balance sheet and improved profitability.

    These strengths are partially offset by a history of uneven cash flow and a softer revenue and earnings performance during 2026. Technical indicators currently present a neutral-to-mixed picture, while valuation appears broadly reasonable rather than particularly inexpensive, especially given the relatively modest dividend yield.

    More About MS International

    MS International plc operates in the defence sector through its wholly owned subsidiary MSI Defence Systems Limited, which is based in Norwich, UK.

    MSI Defence Systems specialises in naval gun systems and integrated weapons technology designed to protect naval platforms against threats across multiple domains. Its systems combine weapon, detection and fire-control technologies, positioning the business to address growing demand for adaptable naval defence capabilities among NATO and allied countries.

  • Tower Resources Raises £325,000 as African Farm-Out Approvals Progress

    Tower Resources Raises £325,000 as African Farm-Out Approvals Progress

    Tower Resources (LSE:TRP) has reported further progress towards securing regulatory approvals for its previously announced farm-out agreements with Prime Global Energies in Namibia and Cameroon. Completion of the approval processes is expected to trigger initial payments and provide access to further funding for the company’s African exploration activities.

    Namibia and Cameroon Approvals Move Forward

    In Namibia, the deed of assignment covering PEL 96 is currently with the Upstream Petroleum Unit for final checks before being submitted for ministerial execution. Completion would allow Tower to move ahead with planned activities across the licence with the financial support of its farm-out partner.

    Progress is also being made in Cameroon, where the approval documentation relating to the Thali licence is awaiting execution at the Presidency. Final approval represents an important step towards funding and advancing the proposed NJOM-3 well.

    The two farm-out transactions are central to Tower’s strategy of bringing in external capital to progress its exploration portfolio while limiting the amount of funding required directly from shareholders.

    Tower Raises £325,000 for Working Capital

    While it waits for proceeds from the farm-out transactions, Tower has raised £325,000 through a subscription for approximately 2.36 billion new shares at a discount to the prevailing market price.

    The company has also granted broker warrants covering around 59.1 million shares, with an exercise price representing a 100% premium to the subscription price.

    Following admission of the newly issued shares, Tower’s total issued share capital will increase to approximately 45.2 billion shares. Although the transaction results in further dilution for existing investors, the proceeds provide additional working capital while the company awaits completion of the regulatory processes and receipt of farm-out funding.

    External Funding Remains Critical

    Tower’s financial position remains challenging, with the company generating no reported revenue while continuing to record losses and negative free cash flow. As an exploration-stage business, it therefore remains dependent on external financing and farm-out partnerships to fund its operations and development plans.

    Technical indicators also remain weak, with the shares trading below major moving averages and signalling an established downward trend. While valuation may appear inexpensive based on certain price-to-earnings measures, such metrics provide limited insight given the company’s underlying losses, lack of operating revenue and continuing cash requirements.

    More About Tower Resources

    Tower Resources is an AIM-quoted oil and gas exploration company focused on upstream opportunities in Africa. Its principal assets include the PEL 96 licence offshore Namibia and the Thali licence in Cameroon.

    The company uses farm-out partnerships as a central part of its financing strategy, bringing in external partners to help fund exploration, appraisal and drilling programmes. Its portfolio provides exposure to frontier and emerging African hydrocarbon basins, although the early-stage nature of its projects carries significant exploration, financing and execution risks.

  • Zephyr Energy Expands Paradox Project Capacity Ahead of Pipeline Approval

    Zephyr Energy Expands Paradox Project Capacity Ahead of Pipeline Approval

    Zephyr Energy (LSE:ZPHR) is investing in additional engineering and well-related work at its Paradox Basin project in Utah as it prepares for potentially higher initial gas production. The decision reflects the board’s confidence that regulatory approval will be obtained to increase operating pressures on Enbridge’s 16-inch pipeline, which would provide greater export capacity for gas produced from the project.

    Gas Processing Capacity Increased to 15 MMscf/d

    Engineering work is progressing on a modular gas processing system designed to handle as much as 15 million standard cubic feet of gas per day. This represents approximately three times the capacity assumed under Zephyr’s previous base-case plans.

    Initial production is expected to come from the State 36-2R and Federal 28-11 wells. Additional volumes could subsequently be introduced from existing and future wells, depending on available cash flow and the receipt of necessary permits.

    By installing infrastructure capable of processing higher volumes from the outset, Zephyr is positioning the Paradox project for a potentially faster ramp-up as it moves towards commercial gas production.

    Enbridge Pipeline Inspection Work Progresses

    Enbridge has completed the mandatory in-line inspection of the pipeline and is now undertaking routine excavation and visual inspection work. No issues have been reported from the process so far.

    Zephyr is carrying out its own field preparations in parallel with this regulatory and inspection work. The strategy is intended to minimise the time between receiving the necessary pipeline approvals and delivering first gas from the Paradox project.

    The company is also continuing discussions regarding a potential farm-out of the project and is progressing a proposed US$15 million commodity purchase agreement. These initiatives could provide additional funding support as Zephyr advances development and seeks to expand production.

    Financial Performance Remains a Constraint

    Zephyr’s outlook continues to be affected by weakening financial performance, including declining revenue, sustained net losses and a significant deterioration in cash generation. Operating and free cash flow were both negative in 2025.

    Technical indicators are more constructive, although an RSI of around 78 points to overbought conditions that could limit confidence in further near-term share price gains. Valuation also provides limited support while the company remains loss-making, resulting in a negative price-to-earnings ratio, while no dividend yield is currently indicated.

    More About Zephyr Energy

    Zephyr Energy plc is a technology-led oil and gas company focused on responsible resource development in the Rocky Mountain region of the United States. Its principal operated asset is the approximately 70,000-acre Paradox project in Utah.

    The project includes the 20,000-acre White Sands Unit, which has independently assessed 2P reserves of 35.3 million barrels of oil equivalent and total recoverable resources of 74.2 million barrels of oil equivalent.

    Zephyr also owns a portfolio of non-operated production interests across the Williston Basin and other parts of the Rocky Mountain region. These assets are supported by a US$100 million strategic partnership intended to accelerate growth and strengthen cash generation as the company expands its regional upstream operations.

  • SkinBioTherapeutics Strengthens Finance Team with Interim CFO Appointment

    SkinBioTherapeutics Strengthens Finance Team with Interim CFO Appointment

    SkinBioTherapeutics (LSE:SBTX) has appointed Anita Slater as interim Chief Financial Officer for an initial six-month period as the life sciences group looks to strengthen its financial governance and controls. Slater will work alongside the existing interim finance team to support a smooth transition and reinforce the company’s financial framework.

    Anita Slater Brings Three Decades of Financial Experience

    Slater is a chartered accountant with around 30 years of senior commercial and financial experience spanning start-ups, AIM-listed companies and FTSE top 10 businesses.

    Her appointment comes as SkinBioTherapeutics focuses on improving its governance structure while progressing the commercial development of its skin health portfolio. Working with the interim finance team, Slater will help ensure continuity across the group’s financial operations during the leadership transition.

    Further Board Appointments Under Discussion

    SkinBioTherapeutics is also in advanced discussions regarding the appointment of additional non-executive directors, signalling that further changes to the board could be forthcoming.

    The company expects to provide a broader business update by mid-September. The planned update, together with potential new board appointments, should provide shareholders with further information on the group’s strategic priorities and evolving leadership structure.

    Profitability and Cash Flow Remain Key Challenges

    SkinBioTherapeutics has delivered strong revenue growth, but its overall financial profile continues to be constrained by negative profitability and cash flow.

    Technical indicators provide some support, with recent trend and momentum signals showing improvement. However, conventional valuation measures remain difficult to assess positively while the company continues to report losses, resulting in a negative price-to-earnings ratio, while no dividend yield is currently indicated.

    More About SkinBioTherapeutics

    SkinBioTherapeutics is an AIM-listed UK life sciences company specialising in skin health. Its operations are built around the proprietary SkinBiotix platform, which originated from research conducted at the University of Manchester.

    The group follows a dual approach to skin health, developing topical products designed to work externally alongside oral supplements intended to support the skin from within. SkinBioTherapeutics also operates contract manufacturing and distribution activities serving the wider skin and healthcare products market.

  • GSK Secures FDA Priority Review for Jemperli as Hibsago Wins First Global Approval in Japan

    GSK Secures FDA Priority Review for Jemperli as Hibsago Wins First Global Approval in Japan

    GSK (LSE:GSK) has reached two significant regulatory milestones across its oncology and hepatology portfolios, with the US Food and Drug Administration granting priority review to Jemperli for certain patients with locally advanced rectal cancer and Japan approving Hibsago as a functional cure for chronic hepatitis B.

    FDA Grants Jemperli Priority Review in Rectal Cancer

    The FDA has accepted GSK’s supplemental biologics application for Jemperli in previously untreated patients with stage II or III mismatch repair deficient or microsatellite instability-high locally advanced rectal cancer.

    The application has been granted priority review and accepted under the FDA’s Project Orbis programme, which is designed to support international collaboration on oncology product reviews. If approved, Jemperli could become the first immunotherapy authorised for this specific treatment setting.

    The submission is supported by results from the phase II AZUR-1 study, which demonstrated a clinically meaningful and sustained complete response lasting at least 12 months. The safety profile was consistent with previous experience using Jemperli across solid tumours.

    The treatment could potentially allow some eligible patients to avoid or postpone chemotherapy, radiation treatment and surgery. Approval would therefore represent a potentially significant change in the treatment pathway for this particular subset of locally advanced rectal cancer while expanding GSK’s presence in oncology immunotherapy.

    Hibsago Secures First Global Approval in Japan

    Separately, Japan’s Ministry of Health, Labour and Welfare has approved GSK’s Hibsago, or bepirovirsen, for the treatment of certain adults with chronic hepatitis B. The decision represents the drug’s first approval worldwide and establishes it as the first functional cure approved for chronic hepatitis B in Japan.

    Hibsago is an antisense oligonucleotide indicated for adults already receiving nucleos(t)ide analogue therapy who meet specified viral marker criteria. The approval addresses a substantial patient population in Japan, where close to one million people are estimated to be living with chronic hepatitis B.

    Japan accelerated the regulatory process through its SENKU designation, which supports therapies intended to address areas of significant unmet medical need.

    Phase III Trials Show 19% Functional Cure Rate

    Approval was supported by GSK’s phase III B-Well programme, in which Hibsago achieved a functional cure rate of 19%, compared with 1% among patients receiving existing standard care.

    For eligible patients, achieving a functional cure could potentially remove the need for lifelong antiviral treatment while reducing the longer-term risks associated with chronic hepatitis B, including liver cancer.

    The Japanese approval also provides an important regulatory milestone as GSK pursues decisions for bepirovirsen in other major markets, including the United States, while building a broader hepatology franchise.

    Strong Financial Profile Supports Pipeline Investment

    GSK’s wider outlook continues to benefit from strong profitability and solid free cash flow generation, alongside a relatively reasonable valuation and an attractive dividend yield.

    Balance-sheet leverage remains a consideration, while earnings and cash conversion have shown some variability. Technical indicators are moderately constructive, with the shares trading above major moving averages, although available momentum signals provide a less complete picture.

    More About GSK

    GSK is a global biopharmaceutical company focused on vaccines and specialty medicines, using science and technology to develop treatments for major diseases.

    Alongside its established businesses, the group is developing a hepatology portfolio targeting chronic and fibro-inflammatory liver diseases. Its areas of research include chronic hepatitis B, metabolic dysfunction-associated steatohepatitis and alcohol-associated liver disease.

  • BATM Advances Strategic Restructuring as Networking and Cyber Operations Build Momentum

    BATM Advances Strategic Restructuring as Networking and Cyber Operations Build Momentum

    BATM Advanced Communications (LSE:BVC) reported a solid first-half performance for 2026 as growth in its core networking operations accompanied further progress with the group’s strategy of disposing of non-core businesses. Adjusted revenue from continuing operations reached $41.7 million, while gross margin remained stable at 34.9% and cash stood at $22.5 million.

    BATM Networks Delivers 20% Revenue Growth

    BATM Networks was a key contributor during the period, with divisional revenue increasing 20% to $8 million. Growth was supported by strong demand for the company’s Carrier Ethernet products as well as its Edgility edge-computing platform.

    The group’s cybersecurity operations also continued to develop new encryption products. Revenue from BATM Cyber declined slightly during the half, although the company attributed the movement primarily to the timing of customer budgets rather than a deterioration in underlying demand.

    Development of advanced cybersecurity technology remains an important part of BATM’s strategy, including solutions designed to provide protection against emerging post-quantum security threats.

    Non-Core Disposals Could Generate $36.6 Million

    BATM made significant progress in simplifying its portfolio during the period, agreeing to dispose of three of its four remaining non-core businesses. The company also completed the sale of an analytical laboratory operation.

    The proposed transactions, together with a related share sale involving one of the divested businesses, are expected to generate approximately $36.6 million in cash.

    These disposals are intended to streamline BATM’s corporate structure, strengthen its balance sheet and release capital for investment in its principal networking and cybersecurity operations. The strategy is increasingly concentrating the group on higher-growth technology areas where management sees stronger long-term opportunities.

    Profitability and Cash Flow Remain Key Challenges

    Despite improving revenue growth and relatively low leverage, BATM’s financial outlook remains constrained by continuing losses and negative operating and free cash flow.

    Technical indicators also remain subdued, with the shares trading below major moving averages, the MACD in negative territory and the RSI below 50. Valuation provides only limited support while the company remains loss-making, resulting in a negative price-to-earnings ratio, while no dividend yield is currently indicated.

    More About BATM Advanced Communications

    BATM Advanced Communications is a global technology company specialising in advanced network infrastructure and cybersecurity solutions. Its growing areas of focus include secure managed networking, edge computing and encryption technologies designed for emerging quantum-era security requirements.

    The group serves customers including governments, critical infrastructure operators and large enterprises, with its strategy increasingly centred on higher-growth and higher-margin networking and cybersecurity markets.

  • GEO Exploration Identifies High-Grade Gold-in-Soil Anomalies at Western Australia Gorge Project

    GEO Exploration Identifies High-Grade Gold-in-Soil Anomalies at Western Australia Gorge Project

    GEO Exploration Limited (LSE:GEO) has reported encouraging soil geochemistry results from its Gorge Project in Western Australia, including a peak assay of 7.74 grams per tonne of gold from the Gorge Mine target. Gold was detected in 99.6% of the 245 samples collected, providing further evidence of widespread mineralisation across the project area.

    Results Strengthen Priority Gold Targets

    The sampling programme identified strong and coherent gold-in-soil anomalies, with several samples returning grades above 1 gram per tonne of gold. The results reinforce the Gorge Mine target and the nearby 401 Prospect as priority areas for further exploration.

    Both targets form part of an approximately five-kilometre mineralised corridor that GEO is evaluating for its potential to host additional gold mineralisation.

    Multi-element geochemical analysis also identified pathfinder element associations consistent with intrusion-related and orogenic gold systems, providing further geological support for the company’s exploration model.

    Expanded Exploration Programme Planned Ahead of Drilling

    Following the latest results, GEO intends to significantly expand its exploration activities at Gorge. The next phase will include approximately 1,188 additional soil samples alongside rock-chip geochemistry and detailed geological mapping.

    The programme is designed to better define the extent of the identified anomalies and allow GEO to refine and rank prospective targets before beginning its planned maiden drilling campaign.

    The latest results increase the exploration potential of the Gorge Project, although drilling will ultimately be required to determine whether the surface geochemical anomalies correspond with significant high-grade mineralisation at depth.

    More About GEO Exploration Limited

    GEO Exploration Limited is a mineral exploration company focused on the discovery and development of gold resources, with the Gorge Project in Western Australia forming a key part of its portfolio.

    The company uses techniques including multi-element soil and rock geochemistry, geological mapping and targeted drilling to identify and advance prospective gold targets along established mineralised corridors.